IL153567A0 - Dual specificity antibodies and methods of making and using - Google Patents

Dual specificity antibodies and methods of making and using

Info

Publication number
IL153567A0
IL153567A0 IL15356701A IL15356701A IL153567A0 IL 153567 A0 IL153567 A0 IL 153567A0 IL 15356701 A IL15356701 A IL 15356701A IL 15356701 A IL15356701 A IL 15356701A IL 153567 A0 IL153567 A0 IL 153567A0
Authority
IL
Israel
Prior art keywords
antibodies
methods
alpha
dual specificity
beta
Prior art date
Application number
IL15356701A
Other languages
English (en)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL153567A0 publication Critical patent/IL153567A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
IL15356701A 2000-06-29 2001-06-28 Dual specificity antibodies and methods of making and using IL153567A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21537900P 2000-06-29 2000-06-29
PCT/US2001/020755 WO2002002773A2 (en) 2000-06-29 2001-06-28 Dual specificity antibodies and methods of making and using

Publications (1)

Publication Number Publication Date
IL153567A0 true IL153567A0 (en) 2003-07-06

Family

ID=22802758

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15356701A IL153567A0 (en) 2000-06-29 2001-06-28 Dual specificity antibodies and methods of making and using
IL153567A IL153567A (en) 2000-06-29 2002-12-20 Dual-specific antibodies that bind two different proteins with a similar structure and method of obtaining it
IL203955A IL203955A (en) 2000-06-29 2010-02-14 A dual-specific antibody that binds two different proteins with a similar structure and method of obtaining it

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL153567A IL153567A (en) 2000-06-29 2002-12-20 Dual-specific antibodies that bind two different proteins with a similar structure and method of obtaining it
IL203955A IL203955A (en) 2000-06-29 2010-02-14 A dual-specific antibody that binds two different proteins with a similar structure and method of obtaining it

Country Status (26)

Country Link
US (5) US7491516B2 (enExample)
EP (4) EP2386575A3 (enExample)
JP (2) JP4955185B2 (enExample)
KR (2) KR100919593B1 (enExample)
CN (3) CN101525384A (enExample)
AT (1) ATE420958T1 (enExample)
AU (1) AU2001271636A1 (enExample)
BG (1) BG66209B1 (enExample)
BR (1) BR0112026A (enExample)
CA (1) CA2411374C (enExample)
CZ (1) CZ2003291A3 (enExample)
DE (1) DE60137421D1 (enExample)
EC (1) ECSP024409A (enExample)
ES (1) ES2319866T3 (enExample)
HU (1) HUP0301002A3 (enExample)
IL (3) IL153567A0 (enExample)
MX (1) MXPA02012867A (enExample)
NO (1) NO20026239L (enExample)
NZ (1) NZ523080A (enExample)
PE (1) PE20020132A1 (enExample)
PL (1) PL208069B1 (enExample)
SK (1) SK1152003A3 (enExample)
TW (2) TWI307716B (enExample)
UY (1) UY26807A1 (enExample)
WO (1) WO2002002773A2 (enExample)
ZA (1) ZA200210109B (enExample)

Families Citing this family (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0996725A1 (en) * 1997-06-27 2000-05-03 Human Genome Sciences, Inc. Human nk-3 related prostate specific gene-1
PE20020132A1 (es) * 2000-06-29 2002-03-04 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
GB0115841D0 (en) 2001-06-28 2001-08-22 Medical Res Council Ligand
JP4303105B2 (ja) * 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20070104710A1 (en) * 2002-06-28 2007-05-10 Domants Limited Ligand that has binding specificity for IL-4 and/or IL-13
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
GB0230201D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Retargeting
US20110223168A1 (en) * 2002-12-27 2011-09-15 Greg Winter Ligand that has binding specificity for il-4 and/or il-13
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US7981843B2 (en) * 2004-01-20 2011-07-19 Kalobios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
TWI439284B (zh) 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
SI1747015T1 (sl) * 2004-04-26 2012-11-30 Janssen Biotech Inc Postopek biopanninga raztopinske faze z uporabo genetsko proizvedenih vabnih proteinov
US7790405B2 (en) 2004-04-26 2010-09-07 Centocor, Inc. Solution phase biopanning method using engineered decoy proteins
US7514539B2 (en) 2004-04-26 2009-04-07 Centocor, Inc. Epitope directed selection of antibodies to murine tissue factor
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
KR20070084069A (ko) 2004-10-08 2007-08-24 도만티스 리미티드 Ｔｎｆｒ1에 대한 단일 도메인 항체 및 이의 사용 방법
EP2361933A3 (en) 2005-01-26 2012-05-02 Amgen Fremont Inc. Antibodies against interleukin-1 beta
KR100675791B1 (ko) * 2005-02-04 2007-02-02 제주대학교 산학협력단 육상어류양식장용 자동먹이공급시스템
CA2608058C (en) 2005-05-12 2013-09-10 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2006136601A1 (en) * 2005-06-23 2006-12-28 Crucell Holland B.V. Optimization of west nile virus antibodies
AU2006272555B2 (en) 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
EP2500353A3 (en) 2005-08-19 2012-10-10 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
EP1940880A2 (en) * 2005-10-14 2008-07-09 Novo Nordisk A/S Treating diabetes using inhibitors of il-1
KR20110079922A (ko) * 2006-04-14 2011-07-11 노파르티스 아게 안과 장애 치료를 위한 ｉｌ－1 항체의 용도
DK2027155T3 (en) * 2006-06-06 2016-05-09 Crucell Holland Bv HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
EP2069534A4 (en) * 2006-08-02 2010-08-11 California Inst Of Techn METHOD AND SYSTEMS FOR DETECTING AND / OR SORTING TARGETS
EP2471816A1 (en) * 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
WO2008077145A2 (en) * 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases
WO2008082651A2 (en) * 2006-12-29 2008-07-10 Abbott Laboratories Dual-specific il-1a/ il-1b antibodies
EP2165194A4 (en) 2007-05-31 2010-09-08 Abbott Lab BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
CA2707637A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US8013125B2 (en) * 2008-03-03 2011-09-06 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
JP2011517662A (ja) 2008-03-03 2011-06-16 ダイアックス コーポレーション メタロプロテアーゼ９結合タンパク質
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2282769A4 (en) * 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2297209A4 (en) * 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
KR20110016959A (ko) * 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US8822645B2 (en) * 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
AR073538A1 (es) 2008-09-03 2010-11-17 Genentech Inc Anticuerpos multiespecificos que se unen especificamente al receptor del factor de crecimiento epidermico humano 2 (her2) y al factor de crecimiento endotelial vascular (vegf)
AU2009289547A1 (en) * 2008-09-05 2010-03-11 Xoma (Us) Llc Methods for treating or preventing IL-1beta related diseases
JP5976319B2 (ja) * 2008-09-12 2016-08-23 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 病原性単球の標的化
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
NZ593905A (en) * 2009-01-29 2013-03-28 Abbott Lab Il-1 binding proteins
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
BRPI1014089A2 (pt) * 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
CN101957365B (zh) * 2009-07-21 2013-08-07 卫生部北京医院 检测抗环瓜氨酸肽和抗免疫球蛋白g双特异性抗体的试剂盒
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2771575A1 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
AR078651A1 (es) * 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AU2010306681A1 (en) * 2009-10-15 2012-04-19 Abbvie Inc. IL-1 binding proteins
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
PH12012501070A1 (en) 2009-12-08 2017-08-23 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
EP2523974A4 (en) * 2010-01-12 2013-11-06 Oncomed Pharm Inc WNT BINDER AND APPLICATIONS THEREOF
WO2011109298A2 (en) 2010-03-02 2011-09-09 Abbott Laboratories Therapeutic dll4 binding proteins
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
TWI500427B (zh) 2010-05-14 2015-09-21 Abbvie Inc Ｉｌ－１結合蛋白
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
CN104474546A (zh) * 2010-08-13 2015-04-01 弗·哈夫曼-拉罗切有限公司 用于疾病治疗的针对IL-1β和IL-18的抗体
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
MX2013007332A (es) 2010-12-21 2014-01-23 Abbvie Inc Inmunoglobulinas de dominio variable doble biespecificas de il-1 alfa y beta y su uso.
RU2563830C2 (ru) 2011-02-08 2015-09-20 Эббви Инк. Лечение остеоартрита и боли
US20140255405A1 (en) 2011-05-27 2014-09-11 Dutalys Removal of Monomeric Targets
SG195196A1 (en) 2011-05-27 2013-12-30 Dutalys Dual targeting
WO2012176779A1 (ja) 2011-06-20 2012-12-27 協和発酵キリン株式会社 抗ｅｒｂＢ３抗体
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
AR088513A1 (es) 2011-10-24 2014-06-18 Abbvie Inc Inmunoenlazantes dirigidos contra esclerostina
UY34410A (es) 2011-10-24 2013-05-31 Abbvie Inc Inmunoligantes biespecificos dirigidos contra tnf
US20140348838A1 (en) * 2011-11-21 2014-11-27 Abbvie Inc. Il-1 binding proteins
RU2482181C1 (ru) * 2011-12-07 2013-05-20 Учреждение Российской академии медицинских наук Российский онкологический научный центр имени Н.Н. Блохина РАМН Клеточная линия d11 множественной миеломы человека, используемая для гибридомной технологии
MX357708B (es) 2011-12-14 2018-07-20 Abbvie Deutschland Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
CN104136462B (zh) 2011-12-14 2017-06-09 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
KR101963230B1 (ko) 2011-12-26 2019-03-29 삼성전자주식회사 복수개의 단일 항체를 포함하는 단백질 복합체
WO2013101972A2 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
AU2013211939C1 (en) 2012-01-27 2018-06-07 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
AR091755A1 (es) 2012-07-12 2015-02-25 Abbvie Inc Proteinas de union a il-1
KR101911438B1 (ko) 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
TW201838651A (zh) * 2012-11-01 2018-11-01 美商艾伯維有限公司 穩定雙重可變區域免疫球蛋白蛋白質調配物
PE20151179A1 (es) 2012-11-01 2015-09-12 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
WO2014089209A2 (en) 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
US9856319B2 (en) 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
EP2938637A2 (en) 2012-12-28 2015-11-04 AbbVie Inc. Multivalent binding protein compositions
US20140219913A1 (en) * 2012-12-28 2014-08-07 Abbvie, Inc. Dual Specific Binding Proteins Having a Receptor Sequence
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
CA2904407A1 (en) 2013-03-15 2014-09-18 Abbvie Inc. Dual specific binding proteins directed against tnf.alpha.
EP3003372B1 (en) 2013-06-07 2019-10-09 Duke University Inhibitors of complement factor h
CN103308697B (zh) * 2013-06-09 2014-11-26 卫生部北京医院 检测抗丙型肝炎病毒编码的非结构蛋白ns3和ns5的天然双特异性抗体的试剂盒
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
US20160271230A1 (en) 2013-09-17 2016-09-22 University Health Network (Uhn): Technology Development And Commercialization Agents directed against a cis rgma/neogenin interaction or lipid rafts and use of the same in methods of treatment
MX2016003617A (es) * 2013-09-30 2016-07-21 Chugai Pharmaceutical Co Ltd Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado.
BR112016011027A2 (pt) * 2013-12-20 2017-12-05 Genentech Inc método de produção de um anticorpo, anticorpos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, método de tratamento de asma e método de tratamento de um distúrbio
PL3140392T3 (pl) 2014-05-06 2023-11-27 F. Hoffmann-La Roche Ag Produkcja białek heteromultimerycznych z wykorzystaniem komórek ssaków
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
WO2015191934A2 (en) 2014-06-11 2015-12-17 Abbvie Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
JP6655302B2 (ja) * 2015-05-29 2020-02-26 デンカ生研株式会社 被検対象の検出方法並びにそのための免疫測定器具及びモノクローナル抗体
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CA2998183A1 (en) 2015-09-11 2017-03-16 AbbVie Deutschland GmbH & Co. KG Methods for treating relapsing forms of multiple sclerosis
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
CN108139394B (zh) * 2015-10-02 2020-10-30 豪夫迈·罗氏有限公司 用于确定同时结合的基于细胞的fret测定法
MA43028B1 (fr) 2015-10-02 2021-09-30 Hoffmann La Roche Anticorps bispécifiques pour pd1 et tim3
WO2017087784A1 (en) 2015-11-18 2017-05-26 Duke University Tumor infiltrating lymphocytes for treatment of cancer
ES2951648T3 (es) 2016-03-11 2023-10-24 Scholar Rock Inc Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas
TW202523689A (zh) 2016-06-01 2025-06-16 美商艾伯維有限公司 治療脊髓損傷及疼痛之方法
EP3515494B1 (en) 2016-09-26 2026-02-25 The Brigham and Women's Hospital, Inc. Regulators of b cell-mediated immunosuppression
CA3036714A1 (en) 2016-10-03 2018-04-12 Abbott Laboratories Improved methods of assessing uch-l1 status in patient samples
CN110382530A (zh) 2017-01-06 2019-10-25 供石公司 亚型特异性、背景许可性TGFβ1抑制剂及其用途
JP7346300B2 (ja) 2017-03-23 2023-09-19 アボット・ラボラトリーズ 早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼｌ１を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法
KR102461885B1 (ko) 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
CA3052532A1 (en) 2017-04-05 2018-10-11 F. Hoffmann-La Roche Ag Bispecific antibodies specifically binding to pd1 and lag3
EP3610268B1 (en) 2017-04-15 2025-09-24 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
JP7080899B2 (ja) 2017-04-28 2022-06-06 アボット・ラボラトリーズ 同じヒト対象に由来する少なくとも２つの試料に対して早期バイオマーカーを使用する、外傷性脳損傷の超急性の診断及び決定の一助となるための方法
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
US10866251B2 (en) 2017-05-25 2020-12-15 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
WO2018222783A1 (en) 2017-05-30 2018-12-06 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers
EP3649474A1 (en) 2017-07-03 2020-05-13 Abbott Laboratories Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
GB201711208D0 (en) 2017-07-12 2017-08-23 Iontas Ltd Ion channel inhibitors
AU2018363922B2 (en) 2017-11-08 2025-06-12 Kyowa Kirin Co., Ltd. Bispecific antibody which binds to CD40 and EpCAM
WO2019113525A2 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
WO2019112860A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
WO2019133717A1 (en) 2017-12-29 2019-07-04 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
KR102891320B1 (ko) 2018-07-11 2025-11-28 스칼러 락, 인크. 고친화도, 이소형-선택적 TGFβ1 억제제 및 그의 용도
EP3820896A1 (en) 2018-07-11 2021-05-19 Scholar Rock, Inc. TGFbeta1 INHIBITORS AND USE THEREOF
PT3677278T (pt) 2018-07-11 2022-02-03 Scholar Rock Inc Inibidores seletivos da isoforma tgfbeta1 e sua utilização
KR102991359B1 (ko) 2018-12-28 2026-07-16 쿄와 기린 가부시키가이샤 TfR에 결합하는 이중 특이적 항체
WO2020180695A1 (en) 2019-03-01 2020-09-10 Abbott Laboratories Methods for predicting major adverse cardiovascular events in subjects with coronary artery disease
WO2020230901A1 (ja) 2019-05-15 2020-11-19 協和キリン株式会社 Ｃｄ４０とｇｐｃ３に結合するバイスペシフィック抗体
CA3140385A1 (en) 2019-05-15 2020-11-19 Kyowa Kirin Co., Ltd. Bispecific antibody binding to cd40 and fap
CA3166328A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
CA3167427A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgfb inhibitors and use thereof
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
CN111793131A (zh) * 2020-05-11 2020-10-20 廊坊天光生物技术有限公司 一种用于检测血清中pf4含量的抗体对及其用途
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
US20220043000A1 (en) 2020-08-04 2022-02-10 Abbott Laboratories Methods and kits for detecting sars-cov-2 protein in a sample
WO2022119841A1 (en) 2020-12-01 2022-06-09 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
AU2022279156A1 (en) 2021-05-18 2023-11-02 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
EP4348260A2 (en) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
WO2022266034A1 (en) 2021-06-14 2022-12-22 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof
WO2023019019A2 (en) * 2021-08-13 2023-02-16 Abwiz Bio, Inc. Humanization, affinity maturation, and optimization methods for proteins and antibodies
CN118715440A (zh) 2021-08-31 2024-09-27 雅培实验室 诊断脑损伤的方法和系统
CA3230038A1 (en) 2021-08-31 2023-03-09 Hongwei Zhang Methods and systems of diagnosing brain injury
WO2023056268A1 (en) 2021-09-30 2023-04-06 Abbott Laboratories Methods and systems of diagnosing brain injury
JP2025503439A (ja) 2021-12-17 2025-02-04 アボット・ラボラトリーズ 血液試料におけるｕｃｈ－ｌ１、ｇｆａｐ及び他のバイオマーカーを決定するためのシステム及び方法
JP2025507303A (ja) 2022-02-04 2025-03-18 アボット・ラボラトリーズ 試料におけるユビキチンカルボキシ末端ヒドロラーゼｌ１及び／又はグリア原線維性酸性タンパク質の存在を検出する又はその量を測定するためのラテラルフロー方法、アッセイ及びデバイス
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
AU2023342055A1 (en) 2022-09-15 2025-03-13 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
EP4676954A1 (en) 2023-03-07 2026-01-14 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
JP2026517628A (ja) 2023-04-04 2026-06-02 アボット・ラボラトリーズ 対象が亜急性後天性脳損傷（ａｂｉ）を負った、負った可能性がある、又は負っていると推測されるかどうかを決定するためのバイオマーカーの使用
WO2024226971A1 (en) 2023-04-28 2024-10-31 Abbott Point Of Care Inc. Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
AU2024386429A1 (en) 2023-11-22 2026-05-21 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
AU2023474055A1 (en) 2023-11-23 2026-06-04 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
WO2025230857A1 (en) 2024-05-01 2025-11-06 Abbott Laboratories Improved methods for determining cardiac myosin binding protein c in biological samples
WO2026112563A1 (en) 2024-11-25 2026-05-28 Abbott Laboratories Systems and methods for tbi adjudication
WO2026152042A1 (en) 2025-01-10 2026-07-16 Scholar Rock, Inc. A novel class of musk agonists and uses thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US126603A (en) 1872-05-07 Improvement in machines for sawing staves
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
FR2577377B1 (fr) * 1985-02-21 1989-06-16 Albaret Sa Procede pour eviter le patinage d'un tracteur equipe d'un relevage hydraulique avec un outil enfoui dans le sol, et equipement de tracteur pour mettre en oeuvre ce procede
US4772685A (en) * 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0642577B1 (en) * 1992-05-22 2004-03-10 Montana State University Antibodies with specificity for multiple adhesion molecules
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
AU698393B2 (en) * 1994-06-24 1998-10-29 Immunex Corporation Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
IL119587A (en) * 1996-11-07 2000-12-06 Univ Ramot Method of preparing and for obtaining bimolecular interactions
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
IL131016A (en) 1997-01-21 2004-12-15 Gen Hospital Corp Selection of proteins using RNA-protein blends
EP0985033A4 (en) 1997-04-04 2005-07-13 Biosite Inc POLYVALENT AND POLYCLONAL LIBRARIES
WO1998049286A2 (en) 1997-05-01 1998-11-05 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6680380B1 (en) 1998-09-18 2004-01-20 Schering Corporation Nucleic acids encoding mammalian interleukin-1ζ, related reagents and methods
BR0009323A (pt) 1999-03-25 2002-01-08 Knoll Gmbh Anticorpos humanos que ligam a il-12 humana e métodos para a produção
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
PE20020132A1 (es) 2000-06-29 2002-03-04 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
CA2632866A1 (en) 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
WO2008082651A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Dual-specific il-1a/ il-1b antibodies
WO2022085430A1 (ja) 2020-10-23 2022-04-28 東レ株式会社 表示装置および表示装置の製造方法

Also Published As

Publication number Publication date
HK1055316A1 (en) 2004-01-02
NZ523080A (en) 2004-11-26
KR100919593B1 (ko) 2009-09-29
HUP0301002A2 (hu) 2003-07-28
EP2899210A3 (en) 2015-11-18
JP4955185B2 (ja) 2012-06-20
ZA200210109B (en) 2004-03-12
US20090232736A1 (en) 2009-09-17
EP2386575A3 (en) 2011-11-30
JP2012031178A (ja) 2012-02-16
US8475766B2 (en) 2013-07-02
MXPA02012867A (es) 2003-09-05
BG66209B1 (bg) 2012-04-30
EP2042518A2 (en) 2009-04-01
ES2319866T3 (es) 2009-05-14
DE60137421D1 (de) 2009-03-05
US7491516B2 (en) 2009-02-17
NO20026239L (no) 2003-02-27
WO2002002773A3 (en) 2002-08-22
CN102120773B (zh) 2013-07-24
WO2002002773A2 (en) 2002-01-10
EP2042518A3 (en) 2009-04-08
JP2004502428A (ja) 2004-01-29
ECSP024409A (es) 2003-02-06
KR20030014288A (ko) 2003-02-15
PL208069B1 (pl) 2011-03-31
BG107483A (bg) 2003-09-30
CN1451043A (zh) 2003-10-22
CN102120773A (zh) 2011-07-13
ATE420958T1 (de) 2009-01-15
US20140155579A1 (en) 2014-06-05
BR0112026A (pt) 2003-05-20
NO20026239D0 (no) 2002-12-27
CN101525384A (zh) 2009-09-09
KR20080074231A (ko) 2008-08-12
IL153567A (en) 2010-11-30
UY26807A1 (es) 2002-01-31
TWI307716B (en) 2009-03-21
SK1152003A3 (en) 2003-07-01
EP2899210A2 (en) 2015-07-29
TW200516083A (en) 2005-05-16
HUP0301002A3 (en) 2005-12-28
AU2001271636A1 (en) 2002-01-14
CA2411374C (en) 2012-10-30
US20150175694A1 (en) 2015-06-25
EP2386575A2 (en) 2011-11-16
CA2411374A1 (en) 2002-01-10
US20030040083A1 (en) 2003-02-27
PE20020132A1 (es) 2002-03-04
EP1297142A2 (en) 2003-04-02
IL203955A (en) 2011-09-27
US20140378666A1 (en) 2014-12-25
EP1297142B1 (en) 2009-01-14
CZ2003291A3 (cs) 2003-05-14
PL359995A1 (en) 2004-09-06

Similar Documents

Publication Publication Date Title
PL359995A1 (en) Dual specificity antibodies and methods of making and using
PL356836A1 (en) Antibodies that bind human interleukin-18 and methods of making and using
LU92159I2 (fr) Ustekinumab et ses dérivés pharmaceutiquement acceptables (STELARA®)
IL206979A0 (en) Il-18 binding proteins
NO2017038I1 (no) Adalimumab - Forlenget SPC
HUP0302589A2 (hu) A béta-amiloid peptidet felismerő humanizált ellenanyagok
TW200745160A (en) IL-12/P40 binding proteins
EP0536275A4 (en) Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
ZA945364B (en) Antibodies specific for human prostate glandular kallikrein
IL164011A0 (en) Antagonistic anti-hfas ligand human antibodies andfragments thereof
EP1411962A4 (en) TREATMENT OF PANCREATIC CANCER WITH A MONOCLONAL ANTIBODY
WO2003011907A3 (de) Rezeptor, dessen verwendung sowie mausantikörper
BR9702101A (pt) Hibridoma e anticorpo monoclonal
SG163559A1 (en) Il-12/p40 binding proteins
MY150711A (en) Il-12/p40 binding proteins